Medherant: Adhesive Patch For Transdermal Drug Delivery
Executive Summary
Medherant Ltd.'s drug delivery patch technology can accommodate medium or low potency drugs at a suitable saturation level to permeate the skin but without compromising adhesion, which existing patch technology has failed to achieve. This means that low potency drugs such as ibuprofen – the company's first product – can now be formulated into a patch rather than only being available in topical gel or cream.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.